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latory care sector the cost decreases over the four years. Every
year the net budget impact due to Aprepitant is less than 3%.
The fourth year, the treatment cost with Aprepitant is equal to
€478,000. CONCLUSION: The additional costs caused by the
introduction of Aprepitant seem fair compared to the gain in
terms of complete control of vomiting.
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OBJECTIVES: To evaluate the economic impact of trastuzumab
treatment in Metastatic Breast Cancer (MBC). Trastuzumab
therapy is initiated in MBC patients over-expressing HER2. The
product is licensed in monotherapy for patients pre-treated with
anthracyclines and taxanes, or associated with paclitaxel for
patients pre-treated by anthracyclines. METHODS: HERMES is
a phase IV multicentric prospective study funded by the French
ministry of health, evaluating the clinical, biochemical and phar-
maco-economic aspect of trastuzumab treatment on MBC.
HER2 status was determined by Immuno-histochemistry or
FISH methods and H-ECD (HER2 Extra-Cellular Domain)
status by ELISA technique. Only HER2 3+ or 2+ and FISH+
patients received treatment. Four protocols were administered:
trastuzumab + paclitaxel weekly (TP1) or three weekly (TP3) and
trastuzumab weekly (T1) or three weekly (T3). Responses were
evaluated according to RECIST criteria then compared to H-
ECD levels. Treatment costs were calculated by adding DGR
costs (2004) and onerous drug reimbursed over DGRs.
RESULTS: In a 3-years period, 120 patients were pre-included
and 88 included. In intention to treat there were 62 TP1, 25 TP3,
and 1 T1. Time to Treatment Failure is 30 weeks [25–35]. 81
patients stopped treatment: 67% for progression, 16% for
cardiac toxicities. Overall survival is 60 weeks [48–80]. Time to
Progression is 34 weeks [27–43]. After 2 months, on 27 patients,
relative risk of progression is of 2.2 for patients with H-ECD
increase. On 22 patients with H-ECD diminution, 20 were
responding to treatment. Overall patient management cost is of
€4,178,000. Average pre-inclusion screening cost is of €829 per
patient. Average treatment cost on 36 weeks reaches €46,345 per
patient including 72% for drug acquisition, 23% for adminis-
tration, 1% for laboratory assessments, 3% for cardiac assess-
ment, 1% for tumour volume assessment. CONCLUSIONS:
From an economic perspective, HER2 assays are cost effective:
they are less expensive than cytotoxic and/or trastuzumab 
treatments.
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OBJECTIVES: To describe treatment patterns and determine
direct medical costs of initiating transdermal opioid systems in
cancer patients with moderate or severe malignant pain. The
study was conducted to test the feasibility of a pharmacoeco-
nomic investigation in the selected patient group. Direct medical
costs per patient and hospital day were calculated from hospital
provider perspective. METHODS: Observational, prospective
cross-sectional study in six units (wards, day clinics) of a uni-
versity hospital. A four-week observation period started with ini-
tiation of the transdermal opioid therapy. Data were obtained
from medical charts and patient diaries. Costs for hospital stay
were only included when pain therapy was the only reason 
for hospital admission. RESULTS: Twenty-eight consecutive
patients with solid tumours were evaluated (gastrointestinal
(39%), urologic (25%), thoracic (14%), CUP (21%). Twelve
patients completed diaries. Participants had a mean age of 61.5
years (range: 38–81), 71% were female and 29% were opioid-
naiv. Six patients died during the observation period. In 71%,
selected doses were in accordance with conversion rates given by
the manufacturers. Mean patch wearing-time was 3.1 days
(range: 2.5–3.6). Average length of stay from ﬁrst patch appli-
cation to hospital discharge was 5.7 days. 39% of the patients
received anti-emetic prophylaxis or treatment and 29% laxatives
to manage opioid side-effects. From hospital provider perspec-
tive mean direct costs were €54 per patient per day. Costs for
hospital stay accounted for the largest portion (€46, 85%). Costs
of pain therapy averaged out €8 (15%), €4 (42%) was analgesic
costs and €4 (51%) application costs. Daily adverse-event man-
agement accounted for €1 per patient. CONCLUSIONS: Costs
for the hospital stay to initiate transdermal opioid therapy were
the major cost driver from hospital provider perspective.
Although constipation and emesis prophylaxis is recommended
by pain management guidelines, in clinical practice a substantial
portion of patients didn’t receive adequate prophylaxis.
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OBJECTIVES: To compare costs of intravenous versus intra-
venous-oral application of cisplatin-etoposide (PE) and cisplatin-
vinorelbine (PN) recommended in NSCLC treatment in Poland.
METHODS: The data of medical resources consumed were col-
lected retrospectively in three major oncology centers in Poland;
among patients with advanced NSCLC (stage IIIb and IV),
treated with intravenous regimen of PE or PN. The payers per-
spective were used and direct medical cost were assessed. All
medical care consumption in intravenous regimen was estimated
from the patients’ medical chart and the information of costs
were derived from the medical valuation system used by
National Fund of Health in 2005. All cost were in polish zloty
(in 2005: 1$ = 3.35 zloty). The resources consumption in com-
bined intravenous-oral regimen was simulated basing on thera-
peutic guidelines of oral regimen of analyzed chemotherapy. We
assume that patient was given intravenous therapy on 1st day
(in both schemes) and oral dose instead of intravenous the fol-
lowing days. Such combination let to reduce the number of hos-
pitalizations due to cytostatics application. RESULTS: The total
costs of PN scheme in intravenous and combined regimen for
one patient was the same and amount to ZL23,416, which
means the savings due to hospitalization were compensate by
increased dose of oral vinorelbine. Despite the increased dose of
oral etoposide the 1228zl difference between intravenous and
combined application was found in PE scheme. The total costs
of treating NSCLC using intravenous and combined PE regimen
were 12,660zl and 11,432zl respectively. CONCLUSIONS: Our
analysis showed that both combinations of intravenous-oral
chemotherapy could be considered as alternatives for intra-
venous regimens.
